18889881171
Kalkine 0
countryflagUS

Adial Pharmaceuticals Inc

Healthcare US ADIL

0.6525USD
-0.0075(1.14%)

Last update at 2025-05-16T16:17:00Z

Day Range

0.640.68
LowHigh

52 Week Range

0.774.17
LowHigh

Fundamentals

  • Previous Close 0.66
  • Market Cap7.56M
  • Volume36403
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.27346M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -12.73192M -19.51740M -10.89299M -8.59143M -11.63138M
Minority interest - - - - -
Net income -12.73142M -19.42333M -10.86050M -8.59143M -11.63138M
Selling general administrative 9.14M 9.34M 5.07M 4.28M 6.62M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.06M 0.06M 0.00056M 0.00056M 0.00056M
Ebit -13.31713M -19.28872M -10.92798M -8.24490M -6.97983M
Ebitda -13.77863M -15.85511M -10.92742M -8.14910M -6.97927M
Depreciation and amortization -0.46150M 3.43M 0.00056M 0.10M 0.00056M
Non operating income net other - - 0.03M -0.34653M -3.47711M
Operating income -13.31713M -19.28872M -10.92798M -8.24490M -6.98722M
Other operating expenses 13.32M 17.74M 10.93M 8.24M 6.99M
Interest expense 0.59M 3.61M 0.00000M 0.00000M 1.17M
Tax provision -0.00050M -0.09408M 0.00000M 0.00000M 0.00000M
Interest income 0.06M 0.00654M 0.03M 0.10M 0.00739M
Net interest income 0.06M 0.00654M 0.03M 0.10M -1.15965M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00050M -0.09408M -0.03250M 0.44M -3.47711M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 13.32M 17.74M 10.93M 8.24M 6.99M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.59M -0.22868M 0.03M -0.34653M -3.48450M
Discontinued operations - - - - -
Net income from continuing ops -12.73142M -19.42333M -10.89299M -8.59143M -11.63138M
Net income applicable to common shares - -19.42333M -10.89299M -8.59143M -11.63138M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.74M 5.73M 7.47M 5.49M 7.68M
Intangible assets 0.00391M 0.46M 0.46M 0.00561M 0.00617M
Earning assets - - - - -
Other current assets 0.37M 0.35M 0.39M 0.50M 0.36M
Total liab 0.65M 2.46M 3.97M 1.51M 0.54M
Total stockholder equity 4.08M 3.28M 3.51M 3.99M 7.14M
Deferred long term liab - - - - -
Other current liab 0.53M 1.34M 0.00968M 0.86M 0.35M
Common stock 0.00166M 0.03M 0.02M 0.01M 0.01M
Capital stock - 0.03M 0.02M 0.01M 0.01M
Retained earnings -68.79787M -63.67453M -50.94311M -31.51979M -20.62680M
Other liab - - 1.04M - -
Good will - 0.25M 0.25M - -
Other assets - - - 0.35M -
Cash 2.83M 4.00M 6.06M 4.40M 6.78M
Cash and equivalents - - - - -
Total current liabilities 0.65M 1.79M 2.72M 1.51M 0.54M
Current deferred revenue - - 2.38M - -
Net debt -2.82708M -3.79442M -5.80521M -4.40111M -6.77705M
Short term debt - 0.06M 0.05M - -
Short long term debt - - - - -
Short long term debt total - 0.21M 0.26M - -
Other stockholder equity 72.88M 66.92M 54.43M 35.49M 27.76M
Property plant equipment - - 0.30M - -
Total current assets 3.20M 4.78M 6.46M 5.14M 7.67M
Long term investments - - - - -
Net tangible assets - - 2.80M 3.98M 7.13M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.13M 0.39M 0.29M 0.65M 0.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.01M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -31.51979M -20.62680M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.53M 0.65M 0.70M 0.35M 0.00617M
Deferred long term asset charges - - - - -
Non current assets total 1.54M 0.95M 1.01M 0.36M 0.00617M
Capital lease obligations - 0.21M 0.26M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -0.03402M -0.35000M - 0.00000M
Change to liabilities - -0.35377M 0.46M 0.28M -0.03481M
Total cashflows from investing activities - -0.03402M -0.35000M -0.35000M -0.35000M
Net borrowings - - - - 0.03M
Total cash from financing activities 9.13M 13.64M 5.61M 9.25M 6.35M
Change to operating activities - 1.46M 0.79M 0.12M -0.65877M
Net income -12.73142M -19.42333M -10.89299M -8.59143M -11.63138M
Change in cash -2.06038M 1.66M -2.37594M 2.91M 3.85M
Begin period cash flow 6.06M 4.40M 6.78M 3.87M 0.02M
End period cash flow 4.00M 6.06M 4.40M 6.78M 3.87M
Total cash from operating activities -11.18599M -11.94943M -7.63316M -6.33861M -2.49839M
Issuance of capital stock 9.12M 11.75M 5.16M 8.20M 6.27M
Depreciation 0.06M 0.06M 0.00056M 0.00056M 0.00056M
Other cashflows from investing activities - - -0.35000M -0.35000M -0.35000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 5.61M 9.25M 6.42M
Other cashflows from financing activities 0.00186M 1.89M 0.45M 1.05M 0.84M
Change to netincome - 5.95M 2.01M 1.60M 9.63M
Capital expenditures 0.00000M 0.06M 0.06M 0.06M 0.06M
Change receivables - - - - -
Cash flows other operating - - 0.16M 0.37M -0.81451M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -2.37594M 2.91M 3.85M
Change in working capital -1.36706M 1.46M 1.25M 0.21M -0.84932M
Stock based compensation 3.37M 4.24M 2.01M 1.60M 5.37M
Other non cash items -0.52200M 1.81M 4.75M 0.44M 1.13M
Free cash flow -11.18599M -12.01403M -7.63316M -6.33861M -2.49839M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ADIL
Adial Pharmaceuticals Inc		 -0.0075 1.14% 0.65 - - - 1.34 -0.4912
NVO
Novo Nordisk A/S		 -2.13 3.22% 64.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.15 3.28% 63.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.34 0.08% 434.04 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.10 0.53% 588.10 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Adial Pharmaceuticals Inc

4870 Sadler Road, Glen Allen, VA, United States, 23060

Key Executives

Name Title Year Born
Mr. Cary John Claiborne MBA CEO, Pres & Director 1961
Mr. Joseph A. M. Truluck M.B.A., MBA CFO, Treasurer & Sec. 1978
Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. Founder & Chief Medical Officer 1960
Mr. John R. Martin J.D. Gen. Counsel NA
Mr. Alex Lugovoy Chief Bus. Officer NA
Dr. Jack W. Reich Ph.D. Head of Regulatory 1949
Mr. Mark H. Peikin Chief Strategy Officer & Chief Devel. Officer NA
Mr. Lawrence Goldman CPA Controller 1956
Ms. Catherine Fratila Controller NA
Mr. Cary John Claiborne MBA CEO, President & Director 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.